| Cash and cash equivalents | |
| Marketable securities | |
| Accounts receivable, net of allowance for doubtful accounts of $630 and $339, respectively | |
| Inventories, net | |
| Prepaid expenses and other current assets | |
| Total current assets | |
| Investments | |
| Property and equipment, net | |
| Intangible assets, net | |
| Other assets | |
| TOTAL ASSETS | |
| Accounts payable and other accrued obligations | |
| Accrued compensation and related expenses | |
| Deferred revenue | |
| Common stock warrant liability | |
| Accrued drug development costs | |
| Total current liabilities | |
| Capital lease obligations | |
| Deferred revenue and other credits--less current portion | |
| Zevalin related contingent obligations | |
| Total liabilities | |
| Commitments and contingencies | |
| Stockholders' Equity: | |
| Preferred stock value | |
| Common stock, $0.001 par value--175,000,000 shares authorized; 52,947,221 and 51,459,284 issued and outstanding at June 30, 2011 and December 31, 2010, respectively | |
| Additional paid-in capital | |
| Accumulated other comprehensive loss | |
| Accumulated deficit | |
| Total stockholders' equity | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | |
| Stockholders' Equity: | |
| Preferred stock value |